Recidivujúci multifokálny leiomyosarkóm močového mechúra 22 rokov po liečbe bilaterálneho (hereditárneho) retinoblastómu: popis prípadu a prehľad literatúry

English version

Autoři: Švajdler M. Jr ¹; L. Valanský ²; I. Andrašina ³; D. Ilenčíková ⁴; L. Copáková ⁵; B. Rychlý ⁶; B. Piačková ⁵
Působiště autorů: Department of Pathology, Louis Pasteur University Hospital, Košice, Slovakia ¹; Department of Urology, Louis Pasteur University Hospital, Košice, Slovakia ²; East Slovakia Oncology Institute, Košice, Slovakia ³; 2nd Department of Paediatrics, Comenius University Medical School, University Children’s Hospital, Bratislava ⁴; Department of Genetics, National cancer institute, Bratislava, Slovakia ⁵; Cytopathos s. r. o., Bratislava, Slovakia ⁶
Vyšlo v časopise: Čes.-slov. Patol., 48, 2012, No. 1, p. 44-48
Kategorie: Původní práce

Souhrn

Popisujeme prípad leiomyosarkómu močového mechúra u 23 ročnej ženy, 22 rokov po liečbe bilaterálneho retinoblastómu. Nádor sa prezentoval dysúriou a makroskopickou hematúriou. Cystoskopicky bol zistený ulcerovaný nádor lokalizovaný v trigone. Následne bola vykonaná jeho transvezikálna resekcia. Osem mesiacov neskôr na inom mieste močového mechúra, vo vertexe, vznikol u pacientky druhý leiomyosarkóm. Bola vykonaná cystoskopická transuretrálna resekcia nádoru s následnou kombinovanou chemoterapiou. Po jednom roku sa objavila recidíva v mieste prvej resekcie. Bola vykonaná otvorená resekcia postihnutej steny mechúra. Dvadsať mesiacov po poslednej operácii je pacientka bez známok recidívy alebo metastáz. Molekulárnou analýzou periférnej krvi bola dokázná vzácna zárodočná bodová mutácia v intróne 24 RB1 génu. FISH analýza nádorového tkaniva dokázala polyploiditu nádorových buniek s relatívnou stratou lókusu RB1, indikujúc ,,second hit” deléciu a tým stratu funkcie druhej RB1 alely. Spolu s desiatimi doposiaľ popísanými prípadmi, náš prípad svedčí pre nenáhodnú asociáciu medzi hereditárnym retinoblastómom a leiomyosarkómom močového mechúra. Dôležitým rizikovým faktorom je pravdepodobne liečba cyklofosfamidom. U týchto pacientov je dôležité celoživotné sledovanie na výskyt sekundárnych malignít, vrátane leiomyosarkómu močového mechúra.

Kľúčové slová:
retinoblastóm – močový mechúr – leiomyosarkóm – sekundárna malignita – cyklofosfamid

Zdroje

1. Cheville, J. Leiomyosarcoma. In: Eble JN, Sauter G, Epstein JI, Sesterhenn IA, eds. WHO classification of tumors. Pathology and genetics of tumors of the urinary system and male genital organs. Lyon: IARC Press; 2004: 140.

2. Martin SA, Sears DL, Sebo TJ, Lohse CM, Cheville JC. Smooth muscle neoplasms of the urinary bladder. A clinicopathologic comparison of leiomyoma and leiomyosarcoma. Am J Surg Pathol 2002; 26(3): 292–300.

3. Pedersen-Bjergaard J, Jonsson V, Pedersen M, Hou-Jensen K. Leiomyosarcoma of the urinary bladder after cyclophosphamide. J Clin Oncol 1995; 13(2): 532–533.

4. Tanguay C, Harvey I, Houde M, Srigley JR, Tźtu B. Leiomyosarcoma of urinary bladder following cyclophosphamide therapy: Report of two cases. Mod Pathol 2003; 16(5): 512–514.

5. Thrasher JB, Miller GJ, Wettlaufer JN. Bladder leiomyosarcoma following cyclophosphamide therapy for lupus nephritis. J Urol 1990; 143(1): 119–121.

6. Al-Zahrani AA, Kamal BA, Eldarawani HM, Hashim TM. Leiomyosarcoma of the bladder in a 16-year-old girl with a history of cyclophosphamide therapy for bilateral retinoblastoma during infancy. Saudi Med J 2006; 27(4): 531–533.

7. Bléoo SL, Godbout R, Rayner D, Tamimi Y, Moore RB. Leiomyosarcoma of the bladder in a retinoblastoma patient. Urol Int 2003; 71(1): 118–121.

8. Brucker B, Ernst L, Meadows A, Zderic S. A second leiomyosarcoma in the urinary bladder of a child with a history of retinoblastoma 12 years following partial cystectomy. Pediatr Blood Cancer 2006; 46(7): 811–814.

9. Kawamura J, Sakurai M, Tsukamoto K, Tochigi H. Leiomyosarcoma of the bladder eighteen years after cyclophosphamide therapy for retinoblastoma. Urol Int 1993; 51(1): 49–53.

10. Liang SX, Lakshmanan Y, Woda BA, Jiang Z. A high-grade primary leiomyosarcoma of the bladder in a survivor of retinoblastoma. Arch Pathol Lab Med 2001; 125(9): 1231–1234.

11. Minagawa T, Okaneya T, Kamigaito M, et al. Leiomyosarcoma of the urinary bladder in a patient with bilateral retinoblastoma. Int J Urol 2008; 15(6): 548–550.

12. Motta L, Porcaro AB, Ficarra V, D’Amico A, Piubello Q, Comunale L. Leiomyosarcoma of the bladder fourteen years after cyclophosphamide therapy for retinoblastoma. Scand J Urol Nephrol 2001; 35(3): 248–249.

13. Parekh DJ, Jung C, O’Conner J, Dutta S, Smith ER Jr. Leiomyosarcoma in urinary bladder after cyclophosphamide therapy for retinoblastoma and review of bladder sarcomas. Urology 2002; 60(1): 164.

14. Venkatraman L, Goepel JR, Steele K, Dobbs SP, Lyness RW, McCluggage WG. Soft tissue, pelvic, and urinary bladder leiomyosarcoma as second neoplasm following hereditary retinoblastoma. J Clin Pathol 2003; 56(3): 233–236.

15. Alonso J, Frayle H, Menendez I, et al. Identification of 26 new constitutional RB1 gene mutations in Spanish, Colombian, and Cuban retinoblastoma patients. Hum Mutat 2005; 25(1): 99.

16. Bisogno G, Sotti G, Nowicki Y, et al. Soft tissue sarcoma as a second malignant neoplasm in the pediatric age group. Cancer 2004; 100(8): 1758–1765.

17. Kleinerman RA, Tucker MA, Tarone RA, et al. Risk of new cancers after radiotherapy in long-term survivors of retinoblastoma: an extended follow-up. J Clin Oncol 2005; 23(10): 2272–2279.

18. Cawenee WK, Hadjistilianou T, Bögler O, Newsham IF. Retinoblastoma syndrome. In: Fletcher CDM, Unni KK, Mertens F, eds. WHO classification of tumors. Pathology and genetics of tumors of soft tissue and bone. Lyon: IARC Press; 2002: 363–364.

19. Evans HL, Shipley J. Leiomyosarcoma. In: Fletcher CDM, Unni KK, Mertens F, eds. WHO classification of tumors. Pathology and genetics of tumors of soft tissue and bone. Lyon: IARC Press; 2002: 130–134.

20. Lefévre SH, Vogt N, Dutrillaux AM, et al. Genome instability in secondary solid tumors developing after radiotherapy of bilateral retinoblastoma. Oncogene 2001; 20(56): 8092–8099.

21. Tsuzuki T, Magi-Galluzzi C, Epstein JI. ALK-1 expression in inflammatory myofibroblastic tumor of the urinary bladder. Am J Surg Pathol 2004; 28(12): 1609–1614.

22. Rabban JT, Zaloudek CJ, Shekitka KM, Tavassoli FA. Inflammatory myofibroblastic tumor of the uterus. A clinicopathologic study of 6 cases emphasizing distinction from aggressive mesenchymal tumors. Am J Surg Pathol 2005; 29(10): 1348–1355.